Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Chemotherapy With or Without Anlotinib in Advanced GBC and ECC
NCT06901622Phase 2Enrolling by invitation
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in gallbladder cancer, extrahepatic cholangiocarcinoma (eCCA), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Nov 2024; status: enrolling by invitation.
02
Drugs
anlotinib
03
Conditions
gallbladder cancerextrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on NCT06901622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901622.